Use of the best case series to evaluate complementary and alternative therapies for cancer: A systematic review

Seminars in Oncology

Volumn 29, Issue 6, 2002, Pages 552-562

  Nahin, Richard L ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Bldg 31 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTON DERIVATIVE; ASCORBIC ACID; HYDRAZINE SULFATE; LAETRILE; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; CANCER REGRESSION; CANCER RESEARCH; CANCER THERAPY; CASE STUDY; HUMAN; PEER REVIEW; PRIORITY JOURNAL; REVIEW; SAFETY; TREATMENT OUTCOME;

EID: 0036970437     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.50004     Document Type: Review

References (63)

1. Bailar JC III, Gomik HL. Cancer undefeated. N Engl J Med 336:1569-1574, 1997
2. Ragnhammar P, Hafstrom L, Nygren P, et al: Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282-308, 2001
3. Adams VR: Adverse events associated with chemotherapy for common cancers. Pharmacotherapy 20:96S-103S, 2000
4. Jansman FG, Sleijfer DT, de Graaf JC, et al: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Safety 24:353-67, 2001
5. Richardson MA, Straus SE: Complementary and alternative medicine: Opportunities and challenges for cancer management and research. Semin Oncol 30:531-545, 2003
6. House of Representatives Subcommittee on Health and Long-term Care of the Select Committee on Aging: Quackery: A $10 Billion Scandal. 98th Congress, 2nd session. Committee Publication 98-435, 1984
7. Byar DP, Simon RM, Friedewald WT, et al: Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 295:74-80, 1976
8. Chalmers I: Evaluating the effects of care during pregnancy and childbirth, in Chalmers I, Enkin M, Keirse MJNC (eds): Effective Care in Pregnancy and Childbirth. New York, NY, Oxford University Press, 1989, pp 4-38
9. Hulley SB, Cummings SR: Designing Clinical Research. Baltimore, MD, Williams & Wilkins, 1988
10. Sackett DL: Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol 9:487-489, 1993
11. National Institutes of Health: Office of Extramural Research: Award Trends. http://grants.nih.gov/grants/award/awardtr.htm, 2002
12. DiMasi JA: New drug development in the United States from 1963-1999. Clin Pharm Ther 69:288-296, 2001
13. DiMasi JA: Risks in new drug development: Approval success rates for investigational rugs. Clin Pharm Ther 69:297-307 2001
14. PhARMA: Pharmaceutical Industry Profile. http://www. phrma.org/publications/, 2000
15. Office of Technology Assessment: Unconventional Cancer Treatments, OTA-H-405. Washington, DC, US Government Printing Office, 1990
16. National Cancer Institute: Office of Cancer Complementary and Alternative Medicine Best Case Series Guidelines, 2002. http://www.cancer.gov/occam/
17. Jenicek M: Clinical Case Reporting in Evidence-Based Medicine. Oxford, UK, Butterworth-Heinemann, 1999
18. Berman BM, Larson DB (eds): Alternative Medicine: Expanding Medical Horizons. NIH Publication 94-066. Bethesda, MD, NIH, 1994
19. Moss RW: The Cancer Industry - Unraveling the Politics. New York, NY, Paragon House, 1989
20. Moss RW: Cancer Therapy: The Independent Consumer's Guide to Non-toxic Treatment and Prevention. New York, NY, Equinox Press, 1994
21. Gonzalez N: One Man Alone: An Investigation of Nutrition, Cancer, and William Donald Kelley: Unpublished book, 1987, cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405; Washington, DC, US Government Printing Office, 1990
22. Gonzalez N: One Man Alone: An Investigation of Nutrition, Cancer, and William Donald Kelley: Unpublished book, 1987, cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405; Washington, DC, US Government Printing Office, 1990
23. Vanchieri C: Alternative therapies getting notice through best case series program. J Natl Cancer Inst 92:1558-1560, 2000
24. Gonzalez NJ, Isaacs LL: Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma. Nutr Cancer 33:115-116, 1999
25. Reed A, James N, Sikora K: Juices, coffee enemas, and cancer. Lancet 336:677-678, 1990
26. Buckner JC, Malkin MG, Reed E, et al: Phase II study of Antineoplastons A10 (NSC 648539). Mayo Clin Proc 74:137-145, 1999
27. Burzynski SR: Efficacy of Antineoplastons A10 and AS2-1. Mayo Clin Proc 74:641-642, 1999
28. Tsuda H, Sata M, Kumabe T, et al: Quick response of advanced cancer to chemoradiation therapy with Antineoplastons. Oncol Rep 5:597-600, 1998
29. Tsuda H, Sata M, Ijuuin H, et al: A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep 9:65-68, 2002
30. Cancer Advisory Panel for Complementary and Alternative Medicine: Meeting Minutes, 1999-2002. http://nccam. nih.gov/about/advisory/capcam/minutes/index.htm
31. Buiatti E, Arniani S, Verdecchia A, et al: Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. Cancer 86:2143-2149, 1999
32. Gerson M: A Cancer Therapy. Results of Fifty Cases (ed 3). Del Mar, CA, Totality Book, 1977
33. Mather JM, Carrothers AWR, Harlow N, et al: Report of a committee of faculty members of the University of British Columbia Concerning the Hoxsey Treatment for Cancer. Vancouver, Canada, University of British Columbia, 1957, as cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405; Washington, DC, US Government Printing Office, 1990
34. Mather JM, Carrothers AWR, Harlow N, et al: Report of a committee of faculty members of the University of British Columbia Concerning the Hoxsey Treatment for Cancer. Vancouver, Canada, University of British Columbia, 1957, as cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405; Washington, DC, US Government Printing Office, 1990
35. Gold J: Use of hydrazine sulfate in terminal and preterminal cancer patients: Results of investigational new drug study in 84 evaluable patients. Oncology 32:1-10, 1975
36. Loprinzi CL, Kuross SA, O'Fallon JR, et al: Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121-1125, 1994
37. Loprinzi CL, Goldberg RM, Su JQ, et al: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1107-1108, 1994
38. Clement RH, Burton L, Lampe GN: Peritoneal mesothelioma. Quantum Med 1:68-73, 1988
39. Moertel CG, Fleming TR, Rubin J, et al: A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med 306:201-206, 1982
40. Monfort H: A new homeopathic approach to neoplastic diseases: From cell destruction to carcinogen-induced apoptosis. Br Homoepathic J 89:78-83, 2000
41. Ellison NM, Byar DP, Newell GR: Special report on laetrile: The NCl laetrile review. N Engl J Med 299:549-552, 1978
42. Livingston-Wheeler V, Addeo ED: The Conquest of Cancer: Vaccines and Diet. New York, NY, Franklin Watts, 1984
43. Carter JP, Saxe GP, Newbold V, et al: Hypothesis: Dietary management may improve survival from nutritionally linked cancers based on analysis of representative cases. J Am Coll Nutr 12:209-226, 1993
44. de la Taille A, Hayek OR, Burchardt M, et al: Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complement Med 6:449-451, 2000
45. Lyall D, Schwartz M, Herter FP, et al: Treatment of cancer by the method of Revici. JAMA 194:279-280, 1965
46. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chemicobiological Interact 9:285-315, 1974
47. Creagan ET, Moertel CG, O'Fallon JR, et al: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301:687-690, 1979
48. Moertel CG, Fleming TR, Creagan ET, et al: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312:137-141, 1985
49. Hennekens CH, Buring JF: Epidemiology in Medicine. Boston, MA, Little Brown, 1987
50. Fletcher RH, Fletcher SW, Wagner EH: Clinical Epidemiology: The Essentials (ed 2). Baltimore, MD, Williams & Wilkins, 1988
51. Office of Alternative Medicine: Minutes of the Alternative Medicine Program Advisory Committee, Sept 1997
52. Hildenbrand GL, Hildenbrand LC, Bradford K, et al: Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: A retrospective review: Altem Ther Health Med 1:29-37, 1995
53. Hildenbrand GL, Hildenbrand LC, Bradford K, et al: The role of follow-up and retrospective data analysis in alternative cancer management: The Gerson experience. J Naturopath Med 6:49-56, 1996
54. Richardson MA, Russell NC, Sanders T, et al: Assessment of outcomes at alternative medicine cancer clinics: A feasibility study. J Altern Complement Med 7:19-32, 2001
55. Shekelle PG, Coulter I, Hurwitz EL, et al: Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America. Ann Intern Med 129:9-17, 1998
56. Hoffman JR: Rethinking case reports. West J Med 170:253-254, 1999
57. Stalker DF: Evidence and alternative medicine. Mt Sinai J Med 62:132-143, 1995
58. Vandenbroucke JP: Case reports in an evidence-based world. J R Soc Med 92:159-163, 1999
59. Tubert P, Begaud B, Pere J-C, et al: Power and weakness of spontaneous reporting: A probabilistic approach. J Clin Epidemiol 45:283-286, 1992
60. Hawkins MJ, Friedman MA: National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst 84:1699-1702, 1992
61. Simon R: How large should a phase II trial of a new drug be. Cancer Treat Rep 71:1079-1085, 1987
62. Vandenbroucke JP: In defense of case reports and case series. Ann Intern Med 134:330-334, 2001
63. National Center for Complementary and Alternative Medicine: Cancer Advisory Panel for Complementary and Alternative Medicine Charter. http://nccam.nih.gov/about/advisory/capcam/, 2002